A genetic link between type 2 diabetes and prostate cancer
- 2.2k Downloads
Epidemiological studies suggest that men with type 2 diabetes are less likely than non-diabetic men to develop prostate cancer. The cause of this association is not known. Recent genetic studies have highlighted a potential genetic link between the two diseases. Two studies have identified a version (allele) of a variant in the HNF1B (also known as TCF2) gene that predisposes to type 2 diabetes, and one of them showed that the same allele protects men from prostate cancer. Other, separate, studies have identified different variants in the JAZF1 gene, one associated with type 2 diabetes, another associated with prostate cancer. These findings are unlikely to completely explain the epidemiological association between the two diseases but they provide new insight into a possible direct causal link, rather than one that is confounded or biased in some way.
KeywordsEpidemiology Genes Genome-wide association study Pleiotropy Prostate cancer Transcription factors Type 2 diabetes
single nucleotide polymorphism
Prostate cancer, BMI and type 2 diabetes
There is extensive but conflicting literature on whether diabetes mellitus is associated with protection from prostate cancer. The extent to which bias and confounding factors could influence this association is also unclear. The most comprehensive meta-analysis performed to date found an inverse association between diabetes and prostate cancer (RR 0.84, 95% CI 0.76–0.93) , but there was significant heterogeneity between studies (p < 0.01). Adjustment for covariates, including BMI, strengthened the association. Two studies reported since this meta-analysis both showed evidence for a reduced risk of prostate cancer in men with type 2 diabetes. The Prostate Cancer Prevention Trial found that diabetes was associated with a 47% reduced risk of low-grade prostate cancer and a 28% reduced risk of high-grade prostate cancer . In another large prospective cohort analysis, diabetes was associated with a 31% lower risk of prostate cancer .
Some data suggest that a reduced incidence of prostate cancer is more pronounced in those with a longstanding elevated risk reported in the first few years after the diagnosis of diabetes [4, 5]. However, another study found the opposite; in the 1959–1972 Cancer Prevention Study there was no overall association between diabetes and prostate cancer incidence, but those with diabetes for 5 or more years had a higher incidence of prostate cancer than did men without diabetes .
The data on the association of either obesity or metabolic syndrome with prostate cancer incidence are also inconsistent. Both elevated and reduced risks have been reported in large, well-designed studies [7, 8, 9, 10]. A recent meta-analysis concluded that the relative risk was 1.05 for every 5 kg/m2 increment in BMI . There is a suggestion that increased BMI is more strongly associated with more severe prostate cancer . For example, in the Prostate Cancer Prevention trial, a BMI of >30 kg/m2 was associated with an 18% lower risk of low-grade prostate cancer and a 29% higher risk of high-grade prostate cancer. However, although all those reaching the end of the trial were offered a prostate biopsy, the protocol referred those with elevations in prostate-specific antigen (PSA) for biopsy earlier in the trial. These data are therefore also consistent with higher BMI being associated with a lower PSA level, which delays diagnosis until disease is more advanced . An increased risk specific to more aggressive disease was also reported in the recent meta-analysis by MacInnis and English .
Diabetes might be associated with prostate cancer in a number of ways; risk factors for one may confer an increased or decreased risk of the other. Mechanisms proposed include differences in insulin levels, bioavailable IGF-1, leptin, free testosterone and drug treatments . Relevant here is that there is some evidence to suggest that oral hypoglycaemic drugs such as metformin may reduce cancer risk [12, 13], and such a hypothesis would be consistent with the greater reduction in risk with longer duration of diabetes observed in some studies [4, 5].
It is also possible that the epidemiological association between type 2 diabetes and prostate cancer could reflect various types of unmeasured biases and confounding factors. For example, if cardiovascular or renal disease and prostate cancer share common risks, then depletion of diabetic cohorts by early mortality will lead to an apparent lower rate of prostate cancer in diabetes survivors. Other, more likely, biases include diagnostic bias, which may be introduced by the less than 100% sensitivity and specificity of different tests, such as PSA screening. In the National Health and Nutrition Examination Survey (NHANES) II, those with diabetes had a 21.6% lower mean PSA level than men without diabetes, and the difference increased with years since diagnosis . This could reflect a true inverse association with prostate cancer; alternatively, it might cause a downward bias in the risk ratio for prostate cancer in type 2 diabetic men because fewer diabetic patients would proceed to diagnostic biopsy. Whether risk or severity of prostate cancer between diabetic and non-diabetic men differs for a given level of PSA is uncertain.
Genome-wide association studies may provide insight into the overlap between different diseases
Genome-wide association studies have recently identified many new common gene variants associated with prevalent diseases, including type 2 diabetes [15, 16]. Most of the genes implicated were not obvious candidates and so provide new insight into similarities in disease aetiology. An additional, important message has emerged from the genome-wide association studies concerning the genetic overlap between different conditions. This is seen most obviously with respect to the autoimmune diseases. For example, several common (non-HLA) variants predispose to type 1 diabetes and at least one other autoimmune disease, including Crohn’s disease, multiple sclerosis and coeliac disease [17, 18, 19, 20].
Two gene loci, three variants and two diseases
A second locus is implicated in both prostate cancer and type 2 diabetes. Thomas et al.  recently reported the results of a genome-wide search for prostate cancer gene variants, which was similar in design to the Gudmundsson et al. study  and replicated the HNF1B findings. The authors also found that carriers of two copies of the G allele at SNP rs10486567, situated in intron 2 of the JAZF1 gene (Fig. 1b), protected individuals from prostate cancer with ORs of 0.71 (95% CI 0.55–0.90) and 0.84 (95% CI 0.67–1.05) for non-aggressive and aggressive forms of the disease, respectively (combined p = 2.4 × 10−6) . At the same time, an independent genome-wide study of type 2 diabetes identified a variant in the JAZF1 gene that predisposed to type 2 diabetes with an OR of 1.10 (95% CI 1.08–1.14, p = 8.8 × 10−12) . The two SNPs reported were not the same, but in the aftermath of the HNF1B finding, the obvious question was whether or not the two variants were correlated with each other and so represented the same genetic signal (as a result of linkage disequilibrium). The answer was negative—the type 2 diabetes and prostate cancer variants are not correlated. This implies that the variants (or those correlated with them) may be operating in completely different ways, and perhaps even on different genes. Nevertheless, the findings from the two loci provide strong evidence that variation in the same genes could affect the risk of these two diseases.
How could DNA variation in the HNF1B and JAZF1 genes influence two diseases?
The recent discovery of these variants means that we know little about how the DNA variation in the HNF1B and JAZF1 genes influence two diseases. We cannot even be certain that the variants alter these genes—it is possible that SNPs in one gene are involved in the control of a second, neighbouring gene. We can therefore only speculate as to the likely mechanisms involved. What we do know is that both gene products are transcription factors that control the expression of many other genes. Both of them are involved in early development. Thus, these genetic associations provide further evidence for the role of general, often early, gene transcription in the aetiology of diabetes. To what extent these genes participate in the long-term maintenance of beta cell mass is unknown. It is also not unusual for transcription factors, or other genes involved in transcriptional processes, to be involved in cancer progression, presumably as a result of the abnormal expression of genes downstream in the pathway.
Studies of HNF1B allow us to speculate about how this transcription factor may be involved in both diseases. We know most about the role of HNF1B in diabetes because of the work following its discovery as a MODY gene, and later as a gene involved in renal disease and other abnormalities . HNF1B is also involved in neoplasia. For example, a combination of germline and somatic HNF1B mutations have been reported in two cases of chromophobe renal cell carcinoma . This means that HNF1B can be classified as a tumour suppressor gene in the kidney. The recent genetic associations with prostate cancer suggest that it can also play this role in the prostate.
There are links between JAZF1 and cancer, but little is known about its possible role in type 2 diabetes. Translocations that result in a fusion protein involving JAZF1 and SUZ12 (also known as JJAZ1) are found in endometrial stromal cell tumours . SUZ12 encodes a ‘polycomb’ protein—a class of proteins involved in chromatin remodelling (the unravelling of the tightly coiled DNA) to control gene expression. The best clue as to the role of JAZF1 in type 2 diabetes comes from the fact that it is involved in the expression of NR2C2, which encodes nuclear receptor subfamily 2, group C, member 2. Mice lacking NR2C2 have neonatal and postnatal hypoglycaemia , a phenotype also observed in humans with HNF4A mutations before they develop diabetes in later life .
More generally, the genetic connection between type 2 diabetes and cancer illustrates a possible scenario in which genes involved in cell cycle proliferation, when suppressed, may lead to inadequate beta cell mass in the adult, giving rise to insufficient insulin secretion and consequent diabetes; conversely, when overactivated in other tissues they might predispose to uncontrolled cellular proliferation. As the genes for more transcription factors (e.g. TCF7L2, HHEX) and cell cycle proteins (e.g. CDKAL1, CDKN2A/B) become associated with diabetes, it will be interesting to explore their possible multiple effects in the various genome-wide cancer datasets.
The cause of the epidemiological association between type 2 diabetes and prostate cancer is not known. However, it is now clear that some genes may be involved in both diseases, and, in the case of HNF1B, a single common polymorphism provides a direct link. Consistent with the epidemiological data, the risk allele for type 2 diabetes is protective for prostate cancer, and vice versa. Further work is needed to assess possible additional genetic links between the two diseases. This intriguing observation may illustrate a general biological phenomenon connecting endocrine pancreatic insufficiency with the inherited susceptibility to neoplasia.
Duality of interest
The authors are not aware of any duality of interest associated with this manuscript.